Aktion

Recombinant Human RET Protein(His Tag)

Recombinant Human RET Protein(His Tag)
Artikelnummer
ELSPDMH100184-1
Verpackungseinheit
1 mg
Hersteller
Elabscience Biotechnology

Verfügbarkeit: wird geladen...
Preis wird geladen...

Special promotion: Enjoy a 10% discount on Elabscience recombinant proteins through September 30, 2025.
Promo code: ELABPQ3
No additional discounts available during this period.

Protein Tag: C-His

Uniprot: P07949

Accession: P07949

Background: RET proto-oncogene, also known as RET, is a cell-surface molecule that transduce signals for cell growth and differentiation. It contains 1 cadherin domain and 1 protein kinase domain. RET proto-oncogene belongs to the protein kinase superfamily, tyr protein kinase family. RET proto-oncogene is involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. It phosphorylates PTK2/FAK1 and regulates both cell death/survival balance and positional information. RET is required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life; promotes the formation of Peyer"s patch-like structures; modulates cell adhesion via its cleavage; involved in the development of the neural crest. RET proto-oncogene is active in the absence of ligand, triggering apoptosis. RET acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and downregulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. It also regulates nociceptor survival and size; triggers the differentiation of rapidly adapting (RA) mechanoreceptors; mediated several diseases such as neuroendocrine cancers. Defects in RET may cause colorectal cancer, hirschsprung disease type 1, medullary thyroid carcinoma, multiple neoplasia type 2B, susceptibility to pheochromocytoma, multiple neoplasia type 2A, thyroid papillary carcinoma and congenital central hypoventilation syndrome.

Bio Acitivity: Not validated for activity

Sequence: Leu29-Arg635

Purity: > 95% as determined by reducing SDS-PAGE.

Formulation: Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.

Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis

Endotoxin: < 1.0 EU/mg of the protein as determined by the LAL method

Calculated MW: 66.7 kDa

Observed MW: 90-120 kDa
Mehr Informationen
Artikelnummer ELSPDMH100184-1
Hersteller Elabscience Biotechnology
Hersteller Artikelnummer PDMH100184-1
Verpackungseinheit 1 mg
Mengeneinheit STK
Produktinformation (PDF)
×
MSDS (PDF)
×